Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693892 | 0.92 | ALDH1A1 (0.49) | KDM4EPARP1CA12CA1CA2 | |
| SCHEMBL2549892 | 0.85 | KDM4E (0.50) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL3318352 | 0.85 | ALDH1A1 (0.63) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL312298 | 0.84 | SRD5A2 (0.53) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL29622719 | 0.83 | TSHR (0.65) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL51027 | 0.83 | TSHR (0.65) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL879015 | 0.83 | ALDH1A1 (0.54) | KDM4EPARP1CA12CA1CA2 | |
| SCHEMBL28866121 | 0.82 | BCAT2 (0.65) | KDM4EPARP1SMN1; SMN2TSHRBCAT2 | |
| SCHEMBL367843 | 0.82 | BCAT2 (0.65) | KDM4EPARP1SMN1; SMN2TSHRBCAT2 | |
| SCHEMBL13736515 | 0.81 | KDM4E (0.58) | KDM4ECA1CA2MGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3561003-A1 | A HYBRID PIGMENT, METHOD FOR PREPARATION THEREOF AND USES THEREOF | Clariant Plastics & Coatings Ltd (CH) | 2019-10-30 | — | — | EP | claimed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| US-7635662-B2 | Compound for color-producing composition, and recording material | CHEMIPRO KASEI KAISHA, LTD. (JP) | 2009-12-22 | — | — | US | claimed |
| CN-1569968-A | Yellow, orange benzimidazolone like azo dye making method | UNIV EAST CHINA SCIENCE & TECH (CN) | 2005-01-26 | — | — | CN | claimed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | claimed |
| US-6548647-B2 | Spraying coupling components in solution or suspension to collide in reactor chamber, then pressurizing to remove; useful for offset printing inks | CLARIANT GMBH (DE) | 2003-04-15 | — | — | US | claimed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020055619-A1 | Process for preparing azo colorants | CLARIANT GMBH | 2002-05-09 | — | — | US | claimed |
| EP-1195411-A1 | Process for the preparation of azo colourants | Clariant GmbH (DE) | 2002-04-10 | — | — | EP | claimed |
| JP-2002501024-A | — | — | 2002-01-15 | — | — | JP | claimed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | claimed |
| US-4288362-A | Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | claimed |
| JP-7165889-A | — | — | None | — | — | JP | disclosed |
| US-12509420-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2025-12-30 | — | — | US | disclosed |
| EP-4144720-B1 | COMPOUND AS UBR-BOX DOMAIN LIGAND | AUTOTAC INC (KR) | 2025-08-27 | — | — | EP | disclosed |
| US-4014863-A | LACQUERS, PRINTING INKS, PAINTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
| US-3957728-A | MODIFIED WITH S-TRIAZINES; ABSORBENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
| US-3953420-A | Azo pigments derived from 2-hydroxy-3-carboxynaphthalene containing a substituted or unsubstituted phthalimide | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | KDM4E 2943/4885PARP1 1298/4885CA12 1412/4885 |
| US-12509420-B2 | Compound as a UBR box domain ligand | UBR4, UBE3A, UBTF | KDM4E 1566/4885PARP1 3300/4885CA12 3069/4885 |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | KDM4E 2024/4885PARP1 421/4885CA12 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.